Regulates paclitaxel sensitivity in ovarian cancer cells by modulating AKT ativation, p21Cip1- and p27Kip1-mediated G1 cell cycle arrest and apoptosis

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Zhang, Shu ^a   Lu, Zhen ^a   Mao, Weiqun ^a   Ahmed, Ahmed A ^a   Yang, Hailing ^a   Zhou, Jinhua ^a   Jennings, Nicholas ^a   Rodriguez Aguayo, Cristian ^a   Lopez Berestein, Gabriel ^a   Miranda, Roberto ^a   Qiao, Wei ^a   Baladandayuthapani, Veera ^a   Li, Zongfang ^b   Sood, Anil K ^a   Liu, Jinsong ^a   Le, Xiao Feng ^a   Bast, Robert C ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 5; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; PACLITAXEL; PROTEIN KINASE B; PROTEIN P53; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT; CDK5 PROTEIN, HUMAN; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CELL CYCLE G1 PHASE; CELL NUCLEUS; CELL VIABILITY; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; GENE SILENCING; GENE TRANSLOCATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; OVARIAN CANCER CELL LINE; OVARY CANCER; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; REGULATORY MECHANISM; TISSUE MICROARRAY; TUMOR XENOGRAFT; UPREGULATION; WILD TYPE; ANIMAL; DRUG SCREENING; GENETICS; METABOLISM; NUDE MOUSE; OVARY TUMOR; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

MUS;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE 5; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; ENZYME ACTIVATION; FEMALE; G1 PHASE; HUMANS; MICE; MICE, NUDE; OVARIAN NEOPLASMS; PACLITAXEL; PROTO-ONCOGENE PROTEINS C-AKT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84940094725     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0131833     Document Type: Article

References (55)

1. Le XF, Mao W, He G, Claret FX, Xia W, Ahmed AA, et al. The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells. Journal of the National Cancer Institute. 2011; 103(18):1403-22. doi: 10.1093/jnci/djr280 PMID: 21813412; PubMed Central PMCID: PMC3176777.
2. Shelton SB, Johnson GV. Cyclin-dependent kinase-5 in neurodegeneration. J Neurochem. 2004; 88 (6):1313-26. PMID: 15009631.
3. Wen Z, Gao C, Wang X, Shi J, Tian B. Analysis of Cdk5-related phosphoproteomics in growth cones. J Mol Neurosci. 2014; 52(3):384-91. doi: 10.1007/s12031-013-0162-x PMID: 24234032.
4. Sun AM, Li CG, Han YQ, Liu QL, Xia Q, Yuan YW. X-ray irradiation promotes apoptosis of hippocampal neurons through up-regulation of Cdk5 and p25. Cancer Cell Int. 2013; 13(1):47. doi: 10.1186/1475-2867-13-47 PMID: 23688022; PubMed Central PMCID: PMC3673899.
5. Odajima J, Wills ZP, Ndassa YM, Terunuma M, Kretschmannova K, Deeb TZ, et al. Cyclin e constrains cdk5 activity to regulate synaptic plasticity and memory formation. Dev Cell. 2011; 21(4):655-68. Epub 2011/09/29. doi: 10.1016/j.devcel.2011.08.009 PMID: 21944720; PubMed Central PMCID: PMC3199337.
6. Liu JL, Wang XY, Huang BX, Zhu F, Zhang RG, Wu G. Expression of CDK5/p35 in resected patients with non-small cell lung cancer: relation to prognosis. Med Oncol. 2011; 28(3):673-8. Epub 2010/04/01. doi: 10.1007/s12032-010-9510-7 PMID: 20354813.
7. Hsu FN, Chen MC, Chiang MC, Lin E, Lee YT, Huang PH, et al. Regulation of androgen receptor and prostate cancer growth by cyclin-dependent kinase 5. J Biol Chem. 2011; 286(38):33141-9. Epub 2011/07/30. doi: 10.1074/jbc.M111.252080 PMID: 21799006; PubMed Central PMCID: PMC3190877.
8. Eggers JP, Grandgenett PM, Collisson EC, Lewallen ME, Tremayne J, Singh PK, et al. Cyclin-dependent kinase 5 is amplified and overexpressed in pancreatic cancer and activated by mutant K-Ras. Clin Cancer Res. 2011; 17(19):6140-50. Epub 2011/08/10. doi: 10.1158/1078-0432.CCR-10-2288 PMID: 21825040.
9. Feldmann G, Mishra A, Hong SM, Bisht S, Strock CJ, Ball DW, et al. Inhibiting the cyclin-dependent kinase CDK5 blocks pancreatic cancer formation and progression through the suppression of Ras-Ral signaling. Cancer research. 2010; 70(11):4460-9. Epub 2010/05/21. doi: 10.1158/0008-5472.CAN-09-1107 PMID: 20484029; PubMed Central PMCID: PMC3071300.
10. Kuo HS, Hsu FN, Chiang MC, You SC, Chen MC, Lo MJ, et al. The role of Cdk5 in retinoic acid-induced apoptosis of cervical cancer cell line. Chin J Physiol. 2009; 52(1):23-30. Epub 2009/09/22. PMID: 19764350.
11. Upadhyay AK, Ajay AK, Singh S, Bhat MK. Cell cycle regulatory protein 5 (Cdk5) is a novel downstream target of ERK in carboplatin induced death of breast cancer cells. Curr Cancer Drug Targets. 2008; 8 (8):741-52. Epub 2008/12/17. PMID: 19075597.
12. Strock CJ, Park JI, Nakakura EK, Bova GS, Isaacs JT, Ball DW, et al. Cyclin-dependent kinase 5 activity controls cell motility and metastatic potential of prostate cancer cells. Cancer research. 2006; 66 (15):7509-15. Epub 2006/08/04. doi: 10.1158/0008-5472.CAN-05-3048 PMID: 16885348.
13. Levacque Z, Rosales JL, Lee KY. Level of cdk5 expression predicts the survival of relapsed multiple myeloma patients. Cell Cycle. 2012; 11(21):4093-5. doi: 10.4161/cc.21886 PMID: 22987154; PubMed Central PMCID: PMC3507504.
14. Simon WE, Albrecht M, Hansel M, Dietel M, Holzel F. Cell lines derived from human ovarian carcinomas: growth stimulation by gonadotropic and steroid hormones. Journal of the National Cancer Institute. 1983; 70(5):839-45. PMID: 6405069.
15. Benard J, Da Silva J, De Blois MC, Boyer P, Duvillard P, Chiric E, et al. Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice. Cancer research. 1985; 45 (10):4970-9. PMID: 3861241.
16. Wilson AP. Characterization of a cell line derived from the ascites of a patient with papillary serous cystadenocarcinoma of the ovary. Journal of the National Cancer Institute. 1984; 72(3):513-21. PMID: 6583437.
17. Alama A, Barbieri F, Favre A, Cagnoli M, Noviello E, Pedulla F, et al. Establishment and characterization of three new cell lines derived from the ascites of human ovarian carcinomas. Gynecologic oncology. 1996; 62(1):82-8. doi: 10.1006/gyno. 1996.0194 PMID: 8690298.
18. Schmidt M, McWatters A, White RA, Groner B, Wels W, Fan Z, et al. Synergistic interaction between an anti-p185HER-2 pseudomonas exotoxin fusion protein [scFv(FRP5)-ETA] and ionizing radiation for inhibiting growth of ovarian cancer cells that overexpress HER-2. Gynecologic oncology. 2001; 80 (2):145-55. doi: 10.1006/gyno. 2000.6040 PMID: 11161852.
19. Rosen DG, Yang G, Deavers MT, Malpica A, Kavanagh JJ, Mills GB, et al. Cyclin E expression is correlated with tumor progression and predicts a poor prognosis in patients with ovarian carcinoma. Cancer. 2006; 106(9):1925-32. doi: 10.1002/cncr.21767 PMID: 16568440.
20. Vervoorts J, Luscher B. Post-translational regulation of the tumor suppressor p27(KIP1). Cell Mol Life Sci. 2008; 65(20):3255-64. doi: 10.1007/s00018-008-8296-7 PMID: 18636226.
21. Philipp-StaheliJ Payne SRKemp CJ. p27(Kip1): Regulation and function of a haploinsufficient tumor suppressor and its misregulation in cancerExp Cell Res.20012641148-6810.1006/excr.2000.5143PMID: 11237531.
22. Ajay AK, Upadhyay AK, Singh S, Vijayakumar MV, Kumari R, Pandey V, et al. Cdk5 phosphorylates non-genotoxically overexpressed p53 following inhibition of PP2A to induce cell cycle arrest/apoptosis and inhibits tumor progression. Mol Cancer. 2010; 9:204. Epub 2010/08/03. doi: 10.1186/1476-4598-9-204 PMID: 20673369; PubMed Central PMCID: PMC2922192.
23. Lee JH, Kim KT. Regulation of cyclin-dependent kinase 5 and p53 by ERK1/2 pathway in the DNA damage-induced neuronal death. J Cell Physiol. 2007; 210(3):784-97. Epub 2006/11/23. doi: 10.1002/jcp.20899 PMID: 17117479.
24. Schmid G, Strosznajder JB, Wesierska-Gadek J. Interplay between the p53 tumor suppressor protein family and Cdk5: novel therapeutic approaches for the treatment of neurodegenerative diseases using selective Cdk inhibitors. Mol Neurobiol. 2006; 34(1):27-50. Epub 2006/09/28. PMID: 17003520.
25. Tsai LH, Delalle I, Caviness VS Jr, Chae T, Harlow E. p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5. Nature. 1994; 371(6496):419-23. Epub 1994/09/29. doi: 10.1038/371419a0 PMID: 8090221.
26. Peterson DW, Ando DM, Taketa DA, Zhou H, Dahlquist FW, Lew J. No difference in kinetics of tau or histone phosphorylation by CDK5/p25 versus CDK5/p35 in vitro. Proc Natl Acad Sci U S A. 2010; 107 (7):2884-9. doi: 10.1073/pnas.0912718107 PMID: 20133653; PubMed Central PMCID: PMC2840295.
27. LandenCN Jr. Chavez-ReyesA Bucana C Schmandt R Deavers MT Lopez-Berestein Get alTherapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery.Cancer research.200565156910-8.10.1158/0008-5472.CAN-05-0530PMID: 16061675.
28. Ahmed AA, Lu Z, Jennings NB, Etemadmoghadam D, Capalbo L, Jacamo RO, et al. SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer. Cancer cell. 2010; 18(2):109-21. doi: 10.1016/j.ccr.2010.06.018 PMID: 20708153; PubMed Central PMCID: PMC3954541.
29. Contreras-Vallejos E, Utreras E, Gonzalez-Billault C. Going out of the brain: non-nervous system physiological and pathological functions of Cdk5. Cell Signal. 2012; 24(1):44-52. doi: 10.1016/j.cellsig.2011. 08.022 PMID: 21924349.
30. Dhariwala FA, Rajadhyaksha MS. An unusual member of the Cdk family: Cdk5. Cell Mol Neurobiol. 2008; 28(3):351-69. doi: 10.1007/s10571-007-9242-1 PMID: 18183483.
31. Brinkkoetter PT, Olivier P, Wu JS, Henderson S, Krofft RD, Pippin JW, et al. Cyclin I activates Cdk5 and regulates expression of Bcl-2 and Bcl-XL in postmitotic mouse cells. J Clin Invest. 2009; 119 (10):3089-101. doi: 10.1172/JCI37978 PMID: 19729834; PubMed Central PMCID: PMC2752065.
32. Kasemeier-Kulesa JC, Teddy JM, Postovit LM, Seftor EA, Seftor RE, Hendrix MJ, et al. Reprogramming multipotent tumor cells with the embryonic neural crest microenvironment. Dev Dyn. 2008; 237 (10):2657-66. doi: 10.1002/dvdy.21613 PMID: 18629870; PubMed Central PMCID: PMC2570047.
33. Demelash A, Rudrabhatla P, Pant HC, Wang X, Amin ND, McWhite CD, et al. Achaete-scute homologue-1 (ASH1) stimulates migration of lung cancer cells through Cdk5/p35 pathway. Mol Biol Cell. 2012; 23(15):2856-66. doi: 10.1091/mbc.E10-12-1010 PMID: 22696682; PubMed Central PMCID: PMC3408413.
34. Hsu FN, Chen MC, Lin KC, Peng YT, Li PC, Lin E, et al. Cyclin-dependent kinase 5 modulates STAT3 and androgen receptor activation through phosphorylation of Ser(7)(2)(7) on STAT3 in prostate cancer cells. Am J Physiol Endocrinol Metab. 2013; 305(8):E975-86. doi: 10.1152/ajpendo.00615.2012 PMID: 23941877.
35. Jin JK, Tien PC, Cheng CJ, Song JH, Huang C, Lin SH, et al. Talin1 phosphorylation activates beta1 integrins: a novel mechanism to promote prostate cancer bone metastasis. Oncogene. 2014. doi: 10. 1038/onc.2014.116 PMID: 24793790.
36. Pozo K, Castro-Rivera E, Tan C, Plattner F, Schwach G, Siegl V, et al. The role of Cdk5 in neuroendocrine thyroid cancer. Cancer Cell. 2013; 24(4):499-511. doi: 10.1016/j.ccr.2013.08.027 PMID: 24135281; PubMed Central PMCID: PMC3849320.
37. Lee JY, Jeong W, Kim JH, Kim J, Bazer FW, Han JY, et al. Distinct expression pattern and post-transcriptional regulation of cell cycle genes in the glandular epithelia of avian ovarian carcinomas. PLoS One. 2012; 7(12):e51592. doi: 10.1371/journal.pone.0051592 PMID: 23236518; PubMed Central PMCID: PMC3517539.
38. Rea K, Sensi M, Anichini A, Canevari S, Tomassetti A. EGFR/MEK/ERK/CDK5-dependent integrinindependent FAK phosphorylated on serine 732 contributes to microtubule depolymerization and mitosis in tumor cells. Cell Death Dis. 2013; 4:e815. doi: 10.1038/cddis.2013.353 PMID: 24091658; PubMed Central PMCID: PMC3824663.
39. Lee KY, Rosales JL, Lee BC, Chung SH, Fukui Y, Lee NS, et al. Cdk5/p35 expression in the mouse ovary. Mol Cells. 2004; 17(1):17-22. PMID: 15055521.
40. Gorrini C, Gang BP, Bassi C, Wakeham A, Baniasadi SP, Hao Z, et al. Estrogen controls the survival of BRCA1-deficient cells via a PI3K-NRF2-regulated pathway. Proceedings of the National Academy of Sciences of the United States of America. 2014; 111(12):4472-7. doi: 10.1073/pnas.1324136111 PMID: 24567396; PubMed Central PMCID: PMC3970526.
41. Ogino S, Lochhead P, Giovannucci E, Meyerhardt JA, Fuchs CS, Chan AT. Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology. Oncogene. 2014; 33(23):2949-55. doi: 10.1038/onc.2013.244 PMID: 23792451; PubMed Central PMCID: PMC3818472.
42. Liu R, Tian B, Gearing M, Hunter S, Ye K, Mao Z. Cdk5-mediated regulation of the PIKE-A-Akt pathway and glioblastoma cell invasion. Proceedings of the National Academy of Sciences of the United States of America. 2008; 105(21):7570-5. doi: 10.1073/pnas.0712306105 PMID: 18487454; PubMed Central PMCID: PMC2396674.
43. Geuna E, Milani A, Martinello R, Aversa C, Valabrega G, Scaltriti M, et al. Buparlisib, an oral pan-PI3K inhibitor for the treatment of breast cancer. Expert opinion on investigational drugs. 2015:1-11. doi: 10. 1517/13543784.2015.1008132 PMID: 25645727.
44. Fujiwara Y, Hosokawa Y, Watanabe K, Tanimura S, Ozaki K, Kohno M. Blockade of the phosphatidylinositol-3-kinase-Akt signaling pathway enhances the induction of apoptosis by microtubule-destabilizing agents in tumor cells in which the pathway is constitutively activated. Molecular cancer therapeutics. 2007; 6(3):1133-42. doi: 10.1158/1535-7163.MCT-06-0639 PMID: 17363506.
45. Ahuja HS, Zhu Y, Zakeri Z. Association of cyclin-dependent kinase 5 and its activator p35 with apoptotic cell death. Dev Genet. 1997; 21(4):258-67. doi: 10.1002/(SICI)1520-6408(1997)21:4<258::AID-DVG3>3.0.CO;2-6 PMID: 9438340.
46. Lin E, Chen MC, Huang CY, Hsu SL, Huang WJ, Lin MS, et al. All-Trans Retinoic Acid Induces DU145 Cell Cycle Arrest through Cdk5 Activation. Cell Physiol Biochem. 2014; 33(6):1620-30. doi: 10.1159/000358724 PMID: 24851929.
47. Brinkkoetter PT, Wu JS, Ohse T, Krofft RD, Schermer B, Benzing T, et al. p35, the non-cyclin activator of Cdk5, protects podocytes against apoptosis in vitro and in vivo. Kidney Int. 2010; 77(8):690-9. doi: 10.1038/ki.2009.548 PMID: 20130526.
48. Wu PC, Tai MH, Hu DN, Lai CH, Chen YH, Wu YC, et al. Cyclin-dependent kinase inhibitor roscovitine induces cell cycle arrest and apoptosis in rabbit retinal pigment epithelial cells. J Ocul Pharmacol Ther. 2008; 24(1):25-33. doi: 10.1089/jop.2007.0044 PMID: 18370874.
49. Wissing MD, Dadon T, Kim E, Piontek KB, Shim JS, Kaelber NS, et al. Small-molecule screening of PC3 prostate cancer cells identifies tilorone dihydrochloride to selectively inhibit cell growth based on cyclin-dependent kinase 5 expression. Oncol Rep. 2014; 32(1):419-24. doi: 10.3892/or.2014.3174 PMID: 24841903.
50. Zheng YL, Li BS, Rudrabhatla P, Shukla V, Amin ND, Maric D, et al. Phosphorylation of p27Kip1 at Thr187 by cyclin-dependent kinase 5 modulates neural stem cell differentiation. Mol Biol Cell. 2010; 21 (20):3601-14. doi: 10.1091/mbc.E10-01-0054 PMID: 20810788; PubMed Central PMCID: PMC2954124.
51. Zhang J, Krishnamurthy PK, Johnson GV. Cdk5 phosphorylates p53 and regulates its activity. J Neurochem. 2002; 81(2):307-13. Epub 2002/06/18. PMID: 12064478.
52. Lin H, Chen MC, Chiu CY, Song YM, Lin SY. Cdk5 regulates STAT3 activation and cell proliferation in medullary thyroid carcinoma cells. J Biol Chem. 2007; 282(5):2776-84. Epub 2006/12/06. doi: 10. 1074/jbc.M607234200 PMID: 17145757.
53. Selvendiran K, Ahmed S, Dayton A, Kuppusamy ML, Rivera BK, Kalai T, et al. HO-3867, a curcumin analog, sensitizes cisplatin-resistant ovarian carcinoma, leading to therapeutic synergy through STAT3 inhibition. Cancer Biol Ther. 2011; 12(9):837-45. Epub 2011/09/03. doi: 10.4161/cbt.12.9.17713 PMID: 21885917.
54. Yusuf RZ, Duan Z, Lamendola DE, Penson RT, Seiden MV. Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets. 2003; 3(1):1-19. PMID: 12570657.
55. Zhang J, Herrup K. Nucleocytoplasmic Cdk5 is involved in neuronal cell cycle and death in post-mitotic neurons. Cell Cycle. 2011; 10(8):1208-14. PMID: 21415596. PMID: 21415596